Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14898127 | 0.91 | KMT2A (0.41) | KMT2ATGM2TSHRDRD2PARP1 | |
| SCHEMBL14898129 | 0.87 | TGM2 (0.39) | KMT2ATGM2PARP1 | |
| SCHEMBL22652455 | 0.86 | KMT2A (0.46) | KMT2ATSHRDRD2PARP1 | |
| SCHEMBL15861719 | 0.84 | KMT2A (0.46) | KMT2ATSHR | |
| SCHEMBL14898171 | 0.82 | TGM2 (0.43) | KMT2ATGM2 | |
| SCHEMBL14879798 | 0.81 | PARP14 (0.44) | TGM2PARP1 | |
| SCHEMBL14879876 | 0.79 | BCHE (0.46) | TGM2PARP1 | |
| SCHEMBL22652456 | 0.77 | CCKBR (0.39) | KMT2APARP1USP30 | |
| SCHEMBL14898131 | 0.76 | KMT2A (0.44) | KMT2ATSHRDRD2 | |
| SCHEMBL1670879 | 0.76 | KMT2A (0.47) | KMT2ATSHRDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11970448-B2 | Monomers capable of dimerizing in an aqueous solution, and methods of using same | CORNELL UNIVERSITY (US) | 2024-04-30 | — | — | US | disclosed |
| US-20200354319-A1 | MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | UNIV CORNELL (US) | 2020-11-12 | — | — | US | disclosed |
| US-20140194383-A1 | MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | CORNELL UNIVERSITY (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194383-A1 | MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | CORNELL UNIVERSITY (US) | 2014-07-10 | — | — | US | disclosed |
| EP-2694707-A1 | MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | Cornell University (US) | 2014-02-12 | — | — | EP | disclosed |
| WO-2013058824-A1 | MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | CORNELL UNIVERSITY (US) | 2013-04-25 | — | — | WO | disclosed |
| WO-2013058824-A1 | MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | CORNELL UNIVERSITY (US) | 2013-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11970448-B2 | Monomers capable of dimerizing in an aqueous solution, and methods of using same | CALCOCO2, MDN1, MBNL1 | KMT2A 4317/4885TGM2 1636/4885TSHR 3797/4885 |
| US-20200354319-A1 | MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | CALCOCO2, MDN1, MBNL1 | KMT2A 4317/4885TGM2 1636/4885TSHR 3797/4885 |
| US-20140194383-A1 | MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | CALCOCO2, MDN1, MBNL1 | KMT2A 4317/4885TGM2 1636/4885TSHR 3797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.